CAD/PAD in Primary Care

Slides:

Advertisements

Similar presentations

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Select Topics in Cardiovascular Medicine

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Surveying the Safety of NOACs in the Real World

How and When to Decide on Revascularization in Stable Ischemic Heart Disease.

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

T2DM and CV Outcomes Trials: A Deep Dive!

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Treatment Options to Consider

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

Understanding PAD.

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Adherence in SPAF: Measures to Improve Care

A Better Solution For Cancer Patients With VTE?

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

Five Things You Need to Know About Secondary Prevention Post-ACS

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

CV Risk Doesn't End in the Cath Lab

Anticoagulation and Thrombosis Management

Aspirin and Cardioprevention in 2018

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Cancer-Associated Thrombosis

CAD and HF Often Coexist

A Case Challenge.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in PAD

Latest Perspectives in PAD: How to Improve Outcomes

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Reassessing Risk Stratification in CAD/PAD

What's New in NOACs in AF?.

Presentation transcript:

CAD/PAD in Primary Care

CV Risk in Stable Outpatients Stratified by Baseline CV Risk Category

Aspirin for Secondary Prevention of CV Disease

Anticoagulant Therapy in CAD Warfarin -- WARIS-2

ATLAS ACS 2 -- TIMI 51 Rivaroxaban vs Placebo After ACS

COMPASS Trial Design

COMPASS Primary Efficacy Outcome -- CV Death/MI/Stroke

COMPASS Cumulative Risk of CV Death/Stroke/MI

COMPASS Bleeding Outcomes

COMPASS CV Death and All-Cause Death

COMPASS: CAD and PAD Cohorts

COMPASS PAD Cohort Peripheral Limb Outcomes

Potential Tolerability Concerns With Adding Rivaroxaban Therapy

Managing Tolerability Concerns

Strategies to Improve Persistence and Adherence to Rivaroxaban Therapy

Correct Dose of Rivaroxaban

VOYAGER PAD

PAD Screening Recommendations

Rivaroxaban FDA Approval: October 15, 2018

External Applicability of the COMPASS Trial REACH Registry

Managing Patients with Stable CAD/PAD in Primary Care

Summary

Abbreviations

Abbreviations (cont)